180 Life Sciences Corp. (ATNF) - Dilution Analysis

10-Q filing | 14.5M shares outstanding

8-K filing: Forum Markets Incorporated, Inc. sold 4,200 Ether at an average price of $1,938.78 per ETH for total proceeds of $8,147,074. ($8.15M proceeds)

S-3 filing: This prospectus relates to the possible resale or other disposition, from time to time, of up to 2,726,983 shares of common stock of ETHZilla Corporation by the selling stockholders named in this prospectus or in supplements to this prospectus.

8-K filing: ETHZilla Corporation entered into a Series B-3 Preferred Stock Purchase Agreement with Zippy, Inc., resulting in the issuance of 1,333,332 shares of ETHZilla's common stock and 202,268 shares to Zippy Stockholders in exchange for shares of Zippy common and preferred stock. ($14.0M proceeds)

8-K filing: ETHZilla Corporation entered into a Purchase and Subscription Agreement with Karus Inc. and Stock Purchase Agreements with certain Karus stockholders, resulting in ETHZilla acquiring 20% of Karus' fully-diluted capitalization. ($7.0M proceeds)

8-K filing: ETHZilla Corporation cancelled 2,099,741 treasury shares of common stock, resulting in 19,301,223 shares outstanding as of November 24, 2025.

10-Q filing | 21.4M shares outstanding

8-K filing: ETHZilla Corporation entered into an Amendment Agreement with an Investor to sell a new series of senior secured convertible notes in the aggregate principal amount of $350 million in exchange for cash equal to 97.25% of the New Principal Amount.

8-K filing: The company authorized a stock repurchase program for up to $250 million and repurchased approximately 3.75 million shares of common stock at an average price of $2.50 per share between September 5, 2025, and September 12, 2025.

8-K filing: ETHZilla Corporation repurchased 2,200,723 shares of its common stock at an average price of $2.50 per share on September 5, 2025.

8-K filing: ETHZilla cancels 1,318,000 shares of its common stock previously held by Elray Resources, Inc. as part of a settlement agreement. ($1.0M proceeds)

8-K filing: Holders of warrants exercised their rights to purchase common stock of 180 Life Sciences Corp., which is changing its name to ETHZilla Corporation, and will have a new ticker symbol, ETHZ, effective August 18, 2025. ($4.52M proceeds)

8-K filing: The Company acquired 82,186 ETH at an average price of $3,806.71, valued at approximately $349 million, using proceeds from a previously disclosed private PIPE offering and sale of convertible notes. ($349.0M proceeds)

8-K filing: 180 Life Sciences Corp. entered into a Securities Purchase Agreement to sell senior secured convertible notes to an institutional investor for $156,250,000 in exchange for cash equal to 96.0% of the principal amount, and also granted additional warrants to purchase an aggregate of 9,071,110 shares of the Company's Common Stock to Strategic Advisors.

8-K filing: 180 Life Sciences Corp. closed a private placement on August 4, 2025, issuing 142,882,173 shares of common stock, pre-funded warrants to purchase 17,495,849 shares, 3,207,560 placement agent shares, and 18,867 consulting shares.

8-K filing: 180 Life Sciences Corp. entered into a securities purchase agreement to sell 160,377,358 shares of common stock at $2.65 per share and pre-funded warrants to purchase up to 16,831,882 shares.

10-Q filing | 5.7M shares outstanding

8-K filing: Acceleration of vesting of stock options and restricted stock awards granted to non-executive directors.

8-K filing: 180 Life Sciences Corp. approved the grant of stock options to purchase shares of common stock to various individuals for services rendered.

S-3 filing: Shelf registration for the potential sale of common stock, preferred stock, debt securities, warrants, or a combination thereof, up to an aggregate initial offering price of $500 million.

8-K filing: Mr. Jay Goodman resigned from the Board of Directors and forfeited 65,000 shares of common stock; the company accelerated the vesting of 65,000 shares of restricted common stock for each of Stephen H. Shoemaker, Dr. Lawrence Steinman and Ryan Smith; the company granted stock options to Ryan Smith, Stephen H. Shoemaker, and Dr. Lawrence Steinman; the company issued 109,541 shares of restricted common stock to Ryan Smith, 72,297 shares of restricted common stock to Stephen H. Shoemaker, and 48,198 shares of common stock to Dr. Lawrence Steinman.

10-Q filing | 5.7M shares outstanding

S-3 filing: Registration statement relating to the resale of shares of common stock by selling stockholders.

8-K filing: 180 Life Sciences Corp. entered into a Settlement and Mutual Release Agreement with Elray Resources, Inc. and Luxor Capital, LLC to acquire 1,318,000 shares of its common stock held by Elray for $1 million. ($1.0M proceeds)

8-K filing: 180 Life Sciences Corp. issued 509,707 shares of common stock to AmTrust Financial Services, Inc. as part of a settlement agreement valued at $575,000. ($0.58M proceeds)

10-K filing | 5.2M shares outstanding

8-K filing: 180 Life Sciences Corp. issued 200,000 shares of restricted common stock to Dr. Marlene Krauss as part of a settlement agreement.

8-K filing: 180 Life Sciences Corp. issued 43,166 shares of restricted common stock to James N. Woody in exchange for the termination of a $50,000 bonus obligation.

S-1/A filing: The company is offering up to 7,092,198 units, each unit consisting of one share of common stock and one and one-half common warrants to purchase one and one-half shares of common stock, at an assumed offering price of $1.41 per unit for gross proceeds of up to $10,000,000, along with pre-funded units and warrants.

S-1/A filing: This is an S-1/A filing which discusses legacy biotechnology programs and warrant transactions, including an August 2023 offering and an amendment to that offering.

8-K filing: 180 Life Sciences Corp. sold 1,200,000 shares of common stock and warrants to purchase up to 1,200,000 shares in a registered direct offering and concurrent private placement at a combined price of $2.41 per share and warrant, with net proceeds of approximately $2.6 million intended for working capital and general corporate purposes.

S-1/A filing: The company is offering up to 5,747,126 units, each unit consisting of one share of common stock and one and one-half common warrants to purchase one and one-half shares of common stock, at an assumed offering price of $1.74 per unit, for gross proceeds of up to $10,000,000, as well as pre-funded units to certain purchasers.

S-1/A filing: This prospectus relates to the offer and sale of up to 1,900,138 shares of common stock of 180 Life Sciences Corp. by the selling stockholder upon exercise of warrants.

S-1 filing: This prospectus relates to the offer and sale of up to 1,900,138 shares of common stock of 180 Life Sciences Corp. by the selling stockholder upon exercise of the October 2024 Warrants.

10-Q filing | 2.0M shares outstanding

8-K filing: On October 16 and 17, 2024, the Existing Warrants were exercised in full for cash, resulting in the issuance of 950,069 shares of Common Stock, and the company received $3,306,240 before deducting financial advisory fees and other expenses. ($3.31M proceeds)

8-K filing: 180 Life Sciences Corp. entered into a warrant inducement agreement with a holder of existing warrants, who agreed to exercise warrants to purchase up to 954,118 shares of common stock at $3.48 per share, with the company issuing new warrants for 200% of the exercised shares at an exercise price of $1.50 per share. ($3.32M proceeds)

8-K filing: 180 Life Sciences Corp. acquired assets from Elray Resources, Inc. in exchange for 1,000,000 shares of Series B Convertible Preferred Stock and warrants to purchase 3,000,000 shares of common stock.

S-1/A filing: The company is offering common stock, pre-funded warrants, and common warrants to purchase common stock.

8-K filing: 180 Life Sciences Corp.'s subsidiary, Cannbiorex Pharma Ltd., entered into a Separation and Release Agreement with Sir Marc Feldmann, issuing 57,328 shares of common stock and options to purchase 20,000 shares of common stock with an exercise price of $1.95.

10-Q filing | 0.9M shares outstanding

S-1 filing: The filing is an S-1 form for an offering of common stock, pre-funded warrants to purchase common stock, and common warrants to purchase common stock.

10-Q filing | 0.9M shares outstanding

POS AM filing: This prospectus relates to the August 2023 Common Warrants and 242,915 shares of the common stock issuable upon exercise of the August 2023 Common Warrants.

POS AM filing: This prospectus relates to the offer and sale of up to 711,203 shares of common stock by the selling stockholder, issuable upon the exercise of various warrants.

10-K filing | 0.9M shares outstanding

8-K filing: 180 Life Sciences Corp. reports the exercise of pre-funded warrants for common stock, resulting in the issuance of 72,000 and 62,000 shares on March 6 and 7, 2024, respectively, after adjusting for a 1-for-19 reverse stock split. After the issuances, the company has approximately 852,758 shares of common stock issued and outstanding; and no pre-funded warrants remain outstanding. ($0.0M proceeds)

8-K filing: On February 28, 2024, a warrant holder exercised warrants to purchase 64,684 shares of common stock at $0.0019 per share for $122.90, following a 1-for-19 reverse stock split. After the issuance, the Company will have approximately 652,292 shares of common stock issued and outstanding. ($0.0M proceeds)

8-K filing: 180 Life Sciences Corp. announces a one-for-19 reverse stock split effective February 28, 2024, and the exercise of warrants to purchase 1,111,878 shares of common stock on February 21, 2024. ($0.0M proceeds)

S-1 filing: This S-1 filing relates to the offer and sale of up to 13,950,976 shares of common stock by the selling stockholder upon exercise of warrants.

8-K filing: 180 Life Sciences Corp. entered into Amendment No. 1 to the August SPA with a Purchaser, agreeing to issue pre-funded warrants to purchase up to 4,886,878 shares of Common Stock and warrants to purchase up to 9,064,098 shares of Common Stock, with the warrants not being exercisable until stockholder approval is obtained. ($1.66M proceeds)

10-Q filing | 8.0M shares outstanding

10-Q filing | 5.2M shares outstanding

8-K filing: 180 Life Sciences Corp. entered into a securities purchase agreement to issue and sell shares of common stock and warrants in a registered public offering, resulting in gross proceeds of approximately $3.0 million. ($3.0M proceeds)

S-1/A filing: This S-1/A filing details the offering of up to 4,716,981 shares of Common Stock, Pre-Funded Warrants, and Common Warrants, with each share of Common Stock or Pre-Funded Warrant sold together with one Common Warrant, at an assumed price of $1.06 per share.

S-1 filing: The filing is an S-1 form detailing a proposed offering of common stock, pre-funded warrants, and common warrants.

10-Q filing | 5.3M shares outstanding

S-1 filing: This prospectus relates to the offer and sale of up to 4,448,713 shares of common stock by the selling stockholder.

8-K filing: 180 Life Sciences Corp. completed a registered direct offering and concurrent private placement on April 10, 2023, issuing 400,000 shares of common stock, pre-funded warrants for 1,170,680 shares, and common warrants for 1,570,680 shares, resulting in gross proceeds of approximately $3.0 million. ($3.0M proceeds)

10-K filing | 3.7M shares outstanding

8-K filing: 180 Life Sciences Corp. amended a warrant agent agreement to reflect that warrants to purchase up to 2,571,429 shares of common stock became exercisable on January 12, 2023.

8-K filing: 180 Life Sciences Corp. amended warrants with an institutional investor, making them exercisable on January 12, 2023, for up to 2,571,429 shares of common stock.

8-K filing: 180 Life Sciences Corp. entered into a securities purchase agreement for the sale and issuance of shares of common stock, pre-funded warrants, and common warrants, resulting in gross proceeds of approximately $6 million, to be used for research and development expenses and general corporate purposes. ($0.0M proceeds)

10-Q filing | 39.2M shares outstanding

10-Q filing | 34.1M shares outstanding

8-K filing: 180 Life Sciences Corp. entered into a securities purchase agreement for a registered direct offering of 3,500,000 shares of common stock, pre-funded warrants to purchase up to 2,632,076 shares, and warrants to purchase up to 6,132,076 shares, with gross proceeds expected to be approximately $6.5 million. ($3.71M proceeds)

POS AM filing: This is a POS AM filing registering the resale of common stock by selling stockholders and the offer and sale of common stock issuable upon the exercise of public warrants.

S-3 filing: The company is filing an S-3 to register an offering of common stock, preferred stock, debt securities, warrants and/or units, up to a total aggregate amount of $125,000,000.

10-Q filing | 34.1M shares outstanding

POS AM filing: The filing registers the resale of common stock by selling stockholders and the offer and sale of common stock issuable upon the exercise of public warrants.

10-K filing | 34.1M shares outstanding

8-K filing: The Company entered into a Consulting Agreement with Lawrence Steinman, M.D., the Company's Executive Co-Chairman, which includes a one-time stock option grant for 25,000 shares of common stock and future annual equity compensation.

10-Q filing | 33.7M shares outstanding

S-1 filing: This S-1 filing relates to the proposed resale of 5,463,658 shares of common stock by selling stockholders.

8-K filing: 180 Life Sciences Corp. issued shares of common stock to Prof Jagdeep Nanchahal in satisfaction of amounts owed for prior work performed, issuing 100,699 shares on March 30, 2021, 37,715 shares on April 15, 2021, and agreeing to issue 61,535 shares on August 23, 2021, all under the Company's 2020 Omnibus Incentive Plan.

8-K filing: 180 Life Sciences Corp. entered into a Securities Purchase Agreement to sell 2,500,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock at $6.00 per share and warrant, with the offering closing on August 23, 2021. ($30.0M proceeds)

POS AM filing: This POS AM filing includes the resale of common stock issued in private transactions, shares issuable upon conversion of convertible preferred stock and promissory notes, and shares issuable upon exercise of warrants.

10-Q filing | 31.5M shares outstanding

POS AM filing: This POS AM filing relates to the resale of common stock by selling stockholders.

S-1 filing: This S-1 filing relates to the proposed resale of 5,436,383 shares of common stock by selling stockholders and the offer and sale of up to 6,001,250 shares of common stock upon the exercise of Public Warrants.

10-Q filing | 30.8M shares outstanding

10-K filing | 30.8M shares outstanding

8-K filing: 180 Life Sciences Corp. sold 2,564,000 shares of common stock and warrants to purchase up to 2,564,000 shares of common stock at a combined price of $4.55 per share and warrant, with the offering closing on February 23, 2021. ($11.7M proceeds)

8-K filing: Holders of convertible promissory notes converted $916,667 of principal and interest into 338,393 shares of common stock at conversion prices between $2.45 and $2.86 per share.

8-K filing: Holders of convertible promissory notes converted $3,162,633 of principal and interest into 1,519,628 shares of common stock, and Dominion Capital, LLC converted 1,000,000 shares of Series A Convertible Preferred Stock into 1,619,144 shares of common stock.

10-Q filing | 5.3M shares outstanding

8-K filing: The company issued 198,751 shares of Common Stock to KBL IV Sponsor LLC upon conversion of a convertible promissory note, 73,629 shares of Common Stock to three holders upon conversion of promissory notes, and 250,000 shares of Common Stock to two vendors in satisfaction of amounts payable.

S-1 filing: This S-1 filing relates to the proposed resale or other disposition from time to time of an aggregate of 9,108,836 shares of the common stock by the selling stockholders.

8-K filing: KBL Merger Corp. IV issued secured convertible promissory notes for $1,000,000 and 100,000 restricted shares of common stock to institutional investors.

10-Q filing | 5.1M shares outstanding

8-K filing: KBL Merger Corp. IV entered into a Securities Purchase Agreement, issuing secured convertible promissory notes and restricted shares of common stock to institutional investors, and filed the Certificate of Designation of the Series A Convertible Preferred Stock.

10-Q filing | 4.5M shares outstanding

10-K filing | 4.2M shares outstanding